Hot Paths

Ironwood boosts outlook on AbbVie’s Linzess (update) (IRWD)

Flipping of 2025 to 2026 on wooden block cube for preparation new year change and start new business target strategy concept.

Dilok Klaisataporn

Shares of Ironwood Pharmaceuticals (IRWD) added ~31% on Friday to hit a new 52-week high after the company set its 2026 revenue outlook ahead of Street forecasts, citing higher net sales from Linzess, a bowel disease therapy it markets in

Exit mobile version